Abingdon Health's performance evaluation laboratory in Doncaster has been accredited to the ISO/IEC 17025:2017 standard by the United Kingdom Accreditation Service. The company says the accreditation supports customers preparing regulatory submissions for diagnostic tests in the UK, EU and US.

What was announced

On 29 September 2026 Abingdon Health plc (LSE:ABDX) said that Abingdon Analytical Ltd, the group's performance evaluation laboratory based in Doncaster, UK, had been granted accreditation to ISO/IEC 17025:2017 by the United Kingdom Accreditation Service (UKAS).

The company described this as the laboratory's first ISO/IEC 17025 accreditation. According to the announcement, the standard assesses whether a laboratory "can consistently produce valid, reliable and defensible results". Abingdon (LSE:ABDX) said the accreditation gives the group's customers "an independently assessed basis for confidence in studies performed within scope".

The announcement does not set out the detailed scope of the accredited activities, such as the specific test methods or assay types covered. It does not give a date on which the accreditation took effect beyond the date of the announcement.

Why it matters to the business

Abingdon Analytical carries out performance evaluation of in vitro diagnostic assays, generating the technical data that manufacturers need for regulatory submissions. Its work covers lateral flow and other diagnostic formats.

The company said the accreditation supports submissions under three regulatory pathways:

Executive Chairman Dr Chris Hand said: "Achieving our first ISO/IEC 17025 accreditation is an important milestone for Abingdon Analytical Ltd. For our customers, the quality of the evidence behind a regulatory submission matters as much as the product itself. Independent UKAS accreditation gives them, and the regulators reviewing their files, clear assurance that our performance evaluation work meets an internationally recognised standard."

The company also said the accreditation strengthens its end-to-end offering, "from diagnostic development and Manufacturing through to regulatory support and market access". In practice, this means a customer can use the group for product development and manufacture as well as for the evaluation data that supports a regulatory file, though the announcement does not quantify how many customers use more than one service.

Background

Abingdon Health was founded in 2008 and is headquartered in York, with facilities in Doncaster and in Madison, Wisconsin, in the US. The group describes three areas of activity:

  • contract development and manufacturing (CDMO) services, focused on lateral flow tests from development to commercial production
  • regulatory services, through its Compliance Solutions and IVDeology businesses
  • analytical testing, through Abingdon Analytical Ltd

Its services span infectious disease, clinical testing, companion diagnostics, and animal and environmental testing.

What the announcement does not say

The update is operational in nature. It contains no revenue, order or Margin figures, and no trading update or guidance. The company has not said whether it expects the accreditation to change pricing, volumes or customer numbers at Abingdon Analytical, and it does not state when or how Abingdon Analytical became part of the group.

Investors looking for the financial effect of the development will need to rely on the company's future trading statements and results, which the announcement does not reference.